Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for the Global Biopharma and Healthcare Sectors
19.5.2026 16:00:00 EEST | Business Wire | Press release
Cohere, the world’s leading sovereign AI company, announced today the acquisition of Reliant AI, a leading biopharma AI company with operations in Montreal and Berlin. This acquisition brings Reliant AI’s world-class research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise-grade sovereign AI platform. This significantly expands Cohere’s footprint in the global healthcare and life sciences sectors–where security, data privacy, and regulatory compliance are paramount—and builds on Cohere’s existing partnerships across administrative, clinical, and revenue cycle workflows.
The acquisition strengthens Cohere’s position as global sovereign AI leader, building on its established presence in Canada and Germany and growing momentum across Europe. Together, Cohere and Reliant AI will equip healthcare and life sciences enterprises with a powerful combination of cutting-edge AI technology, secure deployment options for highly regulated environments, and deep domain expertise to improve processes and bring projects to market faster. This ensures enterprises and governments worldwide can deploy advanced models and systems with full control over their data, infrastructure, and compliance boundaries.
“We’re excited to welcome the Reliant AI team to Cohere as we deepen our work across healthcare and biopharma,” said Aidan Gomez, Co-founder and CEO, Cohere. “Healthcare represents one of the most consequential opportunities for AI and it demands secure, sovereign, and domain-specific systems. Together, we will accelerate progress in healthcare, building on our shared footprint across Canada and Germany to serve these critical sectors. We look forward to bringing North for Pharma to customers and partners as a cornerstone in our expanding portfolio of industry-specific AI products.”
Reliant AI’s flagship product is an intelligent research workbench used by global biopharma organizations to automate systemic literature reviews, competitive landscaping, and extraction of unstructured scientific and regulatory data. The platform also enables rapid identification of therapeutic precedents and modelling of market viability, dramatically accelerating decision-making and time to market.
Reliant was founded in 2023 by Karl Moritz Hermann, Richard Schlegel and Marc G. Bellemare (Canada CIFAR AI Chair, Mila).
"Joining Cohere represents a transformative opportunity to scale our biopharma AI solutions globally while maintaining the security and sovereignty that life sciences organizations require,” said Karl Moritz Hermann, CEO of Reliant AI. “Our combined expertise will accelerate drug discovery and research innovation for customers around the world.”
By integrating these capabilities, Cohere will accelerate the development of North for Pharma, an agentic AI system purpose-built to enhance productivity and efficiency for teams in the biopharma sector working across R&D, clinical development, and scientific analytics. North for Pharma extends Cohere’s growing suite of North offerings for regulated industries, including finance and telecoms. Reliant AI co‑founder and CEO Karl Moritz Hermann will join Cohere as VP of AI Verticalizations in Berlin, while fellow co‑founder Marc Bellemare will serve as VP of Modeling from Montreal.
The deal further unlocks new opportunities across the sector with specialized AI models and solutions tailored to pharmaceutical and biotechnology workflows–addressing challenges that general-purpose AI cannot. As part of the agreement, Cohere will assume Reliant AI’s customer relationships, including GSK, Medicus Pharma, and Kyowa Kirin, and will continue on advancing Reliant AI’s ongoing engagements with major pharmaceutical companies.
About Cohere
Cohere, founded 2019, is a security-first enterprise AI leader building foundation models and end-to-end products to solve business problems. We partner with organizations to deliver seamless integration, customization, and user-friendly solutions. Our all-in-one platform provides maximum security, privacy, and deployment flexibility across clouds, private environments, and on-premises. Headquartered globally in Toronto, San Francisco, Cohere operates additional offices in London, New York, Montreal, Paris, and Seoul, serving customers worldwide.
The company has raised ~$1.6BUSD from strategic tech investors (Nvidia, AMD Ventures, Salesforce Ventures, Oracle, Cisco), institutional investors (Radical Ventures, Inovia Capital, PSP Investments, HOOPP, BDC, Nexxus), and AI pioneers including Geoffrey Hinton, Fei-Fei Li, Pieter Abbeel, and Raquel Urtasun. For more information, visit cohere.com.
About Reliant AI
Reliant AI is the leading gen AI-powered data analytics platform for biopharma. Built by world-class NLP and reinforcement learning researchers with backgrounds at DeepMind, Google Brain, and EY Parthenon, Reliant AI simplifies the process of collecting, organizing, and analyzing complex data to deliver decision-critical insights for life sciences teams. Its flagship product, Reliant Tabular, helps analysts find scientific evidence for their decisions through automated systematic reviews, asset scans, and comprehensive analyses — cutting hours of data wrangling to seconds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260519725513/en/
Contacts
Media Contacts
Cohere
Amanda Taggart
VP, Communications
amanda.taggart@cohere.com
+1 310 980 9587
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Strengthens Global Mobility Capabilities with Collaborating Firm Graebel19.5.2026 16:30:00 EEST | Press release
Andersen Global continues to enhance its multi-dimensional platform through a Collaboration Agreement with Graebel, a global leader in workforce mobility and managed services headquartered in the U.S. with global capabilities spanning the Americas, Europe, and Asia. Founded in 1950, Graebel works with many of the world’s most recognized organizations to simplify the movement and management of talent. The company helps organizations support employees throughout the workforce journey—from internships and onboarding to domestic and international mobility and career transitions—through services that span strategic planning, departure and destination support, on-assignment assistance, repatriation, and mobility program design. Through strategic advisory and intelligent technology, Graebel enables organizations to make more informed decisions and align talent mobility with broader business and workforce strategies through data-driven insights and deep mobility and governance expertise. “Our
Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 16:30:00 EEST | Press release
Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer center. Based in Manchester, they serve a population of 3.2 million people across
Nine in 10 Firms Fear In-House Systems Can’t Keep Pace with Executive Pay Demands19.5.2026 16:00:00 EEST | Press release
Managing executive compensation is a growing challenge for financial services firms, with nearly nine in 10 (89%) saying their in-house technology can’t keep pace with demand. New research by CSC, the leading provider of business administration and compliance solutions, shows that rising complexity, regulatory pressure, and expanding global participation place increasing strain on internal systems and teams.1 CSC surveyed 300 senior HR, rewards, and compensation leaders across Europe, Asia Pacific, and North America working in private markets, asset management, insurance, and investment banking. The report, The Future of Reward in Financial Services: Executive Compensation in 2026, explores their responses and examines how firms adapt to increasing complexity in long-term incentive (LTI) schemes. The research revealed that more than four in five (86%) respondents find the administration of compensation schemes is now complex, reflecting the rapid evolution and expansion of LTI structur
Tacton Appoints Manufacturing Technology Leader Mike DiTullio to Board of Directors19.5.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the appointment of Mike DiTullio to its Board of Directors. DiTullio is an enterprise software executive with more than three decades of experience working with complex manufacturers. He joins at a pivotal moment in the company’s evolution as Tacton expands beyond CPQ to deliver the Buyer-Centric Smart Factory, a connected approach that unites buyer engagement, engineering, and order fulfillment into a single intelligent system. DiTullio spent 26 years at PTC, most recently as President and Chief Operating Officer, wherehe worked closely with leading manufacturers to transform how they design, sell, and deliver complex products. In that role, he led global commercial operations across seven business units representing more than $1.5 billion in annual revenue and guided the company through its transition to a subscription-based, digital-first business model. His deep
Echodyne and Moog Successfully Demonstrate Reconfigurable Integrated-weapon Platform (RIwP®) at U.S. Army Exercise19.5.2026 16:00:00 EEST | Press release
Echodyne, the radar platform company, and Moog Inc. (NYSE: MOG.A and MOG.B), a worldwide designer, manufacturer, and systems integrator of high performance precision motion and control systems, announce the results of testing of their defensive systems to counter small offensive UAS (“sUAS”) weapons. Capabilities Tested Live detection, lock on with precision tracking, and successfully engaging of Group 1-3 UAS threats in less than 3 seconds. Combined AI targeting, wireless fire control, and radar integration across mission equipment capabilities for defense against small UAS weapons. AI targeting for passive detection, autonomous targeting, track re-acquire, multi-object targeting. Outputs Identified and swiftly rectified critical capability gaps within a simulated battlefield environment. Proved that combining precision data with AI firing solution computation is a cost-effective solution for rapidly upgrading existing kinetic weapon stations to highly effective C-UAS systems. One of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom